Direct Vasodilators and Sympatholytic Agents
June 2015
in “
Journal of cardiovascular pharmacology and therapeutics
”
New to Minoxidil? There is a guide in the encyclopedia. Read the guide → Studysummary This article discusses the use of direct vasodilators and sympatholytic agents in hypertension management, highlighting their utility in specific cases like refractory hypertension and heart failure, but reports no new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document reviewed the use of direct vasodilators and sympatholytic agents, such as hydralazine and clonidine, in managing cardiovascular diseases, particularly hypertension and heart failure. Despite reduced use due to side effects and newer drug classes, these agents showed comparable blood pressure-lowering effects. Hydralazine had niche applications, including refractory hypertension, renal dysfunction, and pregnancy-induced hypertension, and was beneficial in combination with isosorbide dinitrate for systolic heart failure in African American patients. Minoxidil was effective for severe hypertension and renal dysfunction but had side effects like tachycardia and hypertrichosis. Alpha-1 adrenergic blockers (prazosin, terazosin, doxazosin) and alpha-2 adrenergic agonists (clonidine, methyldopa) were also discussed for their efficacy and side effects. The document emphasized the importance of these drugs in combination therapies, especially for patients with renal impairment, despite limited robust clinical trial data.
